BAY 73-6691 (CAS 794568-92-6)
See product citations (2)
QUICK LINKS
BAY 73-6691 is a potent and selective inhibitor of the phosphodiesterase 9 (PDE9) enzyme, which plays a role in the cyclic guanosine monophosphate (cGMP) signaling pathway. By inhibiting PDE9, BAY 73-6691 increases cGMP levels within cells, thereby modulating various cellular functions that are dependent on this signaling pathway. The increased concentration of cGMP can affect the regulation of ion channels, intracellular calcium levels, and other molecular processes critical for cellular function and communication. In research applications, BAY 73-6691 is utilized to study the role of the cGMP pathway in cellular processes and to investigate the potential therapeutic targets for diseases where cGMP dysregulation is implicated. Its selective action on PDE9 makes it useful for dissecting the specific contributions of this enzyme to cellular signaling networks and understanding how modulation of cGMP levels can influence cellular physiology and pathology in various experimental models.
BAY 73-6691 (CAS 794568-92-6) References
- The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. | van der Staay, FJ., et al. 2008. Neuropharmacology. 55: 908-18. PMID: 18674549
- Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. | Miguel, LI., et al. 2011. Inflamm Res. 60: 633-42. PMID: 21336703
- Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. | Kroker, KS., et al. 2012. Neuropharmacology. 62: 1964-74. PMID: 22245562
- Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. | Saravani, R., et al. 2012. Cell Prolif. 45: 199-206. PMID: 22469131
- The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice. | Liddie, S., et al. 2012. J Psychopharmacol. 26: 1375-82. PMID: 22596207
- Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice. | da Silva, FH., et al. 2013. Int J Impot Res. 25: 69-73. PMID: 23034509
- Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. | Orrú, M., et al. 2013. Neuropharmacology. 67: 476-84. PMID: 23261866
- PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. | Kroker, KS., et al. 2014. Neurobiol Aging. 35: 2072-8. PMID: 24746365
- The Effect of a Selective Inhibitor of Phosphodiesterase-9 on Oxidative Stress, Inflammation and Cytotoxicity in Neutrophils from Patients with Sickle Cell Anaemia. | Barbosa, MC., et al. 2016. Basic Clin Pharmacol Toxicol. 118: 271-8. PMID: 26346295
- Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease. | Li, J., et al. 2016. Brain Res. 1642: 327-335. PMID: 27071547
- Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses. | Prieto, GA., et al. 2017. J Neurosci. 37: 1197-1212. PMID: 27986924
- Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation. | Tajima, T., et al. 2018. J Vet Med Sci. 80: 499-502. PMID: 29386424
- Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. | Wu, XN., et al. 2018. Acta Pharm Sin B. 8: 615-628. PMID: 30109185
- Hydrolysis of the non-canonical cyclic nucleotide cUMP by PDE9A: kinetics and binding mode. | Scharrenbroich, J., et al. 2019. Naunyn Schmiedebergs Arch Pharmacol. 392: 199-208. PMID: 30443663
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAY 73-6691, 5 mg | sc-252407 | 5 mg | $247.00 |